Bilaketaren emaitzak - Kalpana Shah

  • Erakusten 1 - 4 emaitzak -- 4
Findu emaitzak
  1. 1
    Rates, indications, and outcomes of caesarean section deliveries: A comparison of tribal and non-tribal women in Gujarat, India

    Rates, indications, and outcomes of caesarean section deliveries: A comparison of tribal and non-tribal women in Gujarat, India nork Gayatri Desai, Ankit Anand, Dhiren Modi, Shobha Shah, Kalpana Shah, Ajay M. Shah, Shrey Desai, Pankaj Shah

    Argitaratua 2017
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule

    Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule nork Alexey Berezhnoy, Bradley Sumrow, Kurt Stahl, Kalpana Shah, Daorong Liu, Jonathan Li, Su-Shin Hao, Anushka De Costa, Sanjeev Kaul, Johanna C. Bendell, Gregory M. Coté, Jason J. Luke, Rachel E. Sanborn, Manish Sharma, Francine Chen, Hua Li, Gundo Diedrich, Ezio Bonvini, Paul A. Moore

    Argitaratua 2020
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal Cancer

    Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal Cancer nork Paul A. Moore, Kalpana Shah, Yinhua Yang, Ralph Alderson, Penny Roberts, Vatana Long, Daorong Liu, Jonathan Li, Steve Burke, Valentina Ciccarone, Hua Li, Claudia Fieger, Jeff Hooley, Ann Easton, Monica Licea, Sergey Gorlatov, Kathy L. King, Peter Young, Arash Adami, Deryk Loo, Gurunadh R. Chichili, Liqin Liu, Douglas H. Smith, Jennifer G. Brown, Francine Z. Chen, Scott Koenig, Jennie P. Mather, Ezio Bonvini, Syd Johnson

    Argitaratua 2018
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  4. 4
    The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial

    The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial nork Jason J. Luke, Manish R. Patel, George R. Blumenschein, Erika Hamilton, Bartosz Chmielowski, Susanna V. Ulahannan, Roisín M. Connolly, Cesar A. Santa‐Maria, Jie Wang, Shakeela Bahadur, Andrew Weickhardt, Adam S. Asch, Girish Mallesara, Philip R. Clingan, Monika Długosz‐Danecka, Monika Tomaszewska‐Kiecana, Halyna Pylypenko, Nada Hamad, Hedy L. Kindler, Bradley Sumrow, Patrick Kaminker, Francine Z. Chen, Xiaoyu Zhang, Kalpana Shah, Douglas H. Smith, Anushka De Costa, Jonathan Li, Hua Li, Jichao Sun, Paul A. Moore

    Argitaratua 2023
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: